Applications and validation analyses shown in the manuscript
The two network files used in the case scenario.
To validate the disease-drug pairs prioritized by Drug2ways, we used clinical trial information (i.e., drugs that have been tested on a given indication) from ClinicalTrials.gov mapped to each of the networks.
If you use drug2ways for your research please cite our paper:
Daniel Rivas-Barragan, Sarah Mubeen, Francesc Guim-Bernat,Martin Hofmann-Apitius, and Daniel Domingo-Fernández (2020). Drug2ways: Reasoning over causal paths in biological networks for drug discovery. PLOS Computational Biology 16(12): e1008464; https://doi.org/10.1371/journal.pcbi.1008464